Eastman Chemical (EMN) is rated 'Buy' with a price target of $104 per share, indicating over 15% annualized upside. The company's strength lies in its leadership in molecular recycling and specialty materials, which supports long-term growth despite recent earnings declines and volume weakness due to macroeconomic factors. EMN's strong cash flow, a well-covered 4.5% dividend, and an investment-grade balance sheet provide downside protection. Expected cost reductions, increased recycling efforts, and market stabilization should drive 5-7% annual earnings growth through 2026 and beyond.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
